OLEMA PHARMACEUTICALS INC (OLMA)

Company Profile

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of targeted therapies for women's cancers. The company is headquartered in San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2020-11-19. The firm is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). The firm's OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including ESR1 and PIK3CA mutations and central nervous system (CNS), metastasis. The company is in the Phase I/ II clinical trial, and in Phase Ib/ II combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Company Info

OLEMA PHARMACEUTICALS INC

780 Brannan Street

San Francisco CALIFORNIA 94107

P: 14156513316

CEO: Sean Bohen

Employees: 70

Website: https://olema.com/